Dl-3-n-butylphthalide and Cerebrolysin Treatment in Acute Ischemic Stroke


Phase 1/2 Results

Summary of Purpose

The investigators conducted a randomized, double-blind, trial enrolled 60 patients within 12 hours of acute ischemic stroke (AIS) in China. Patients were randomly assigned to receive a 10-day infusion of dl-3-n-butylphthalide (NBP) or cerebrolysin, or placebo. National Institutes of Health Stroke Scale (NIHSS) and Barthel Index (BI) were used to evaluate the efficacy in the patients with AIS at 11-day and 21-day...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 18 May 2016.

1 Jan 2010 16 May 2014 1 May 2010 1 May 2010 1 May 2016 12 Apr 2016
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment


Not available